SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects

Patrizia Damonte, Giovanna Sociali, Marco Daniele Parenti, Debora Soncini, Inga Bauer, Silvia Boero, Alessia Grozio, Maria von Holtey, Francesco Piacente, Pamela Becherini, Roberta Sanguineti, Annalisa Salis, Gianluca Damonte, Michele Cea, Maximilien Murone, Alessandro Poggi, Alessio Nencioni, Alberto Del Rio, Santina Bruzzone

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The NAD+-dependent deacetylase SIRT6 is an emerging cancer drug target, whose inhibition sensitizes cancer cells to chemo-radiotherapy and has pro-differentiating effects. Here we report on the identification of novel SIRT6 inhibitors with a salicylate-based structure. The new SIRT6 inhibitors show improved potency and specificity compared to the hit inhibitor identified in an in silico compound screen. As predicted based on SIRT6 biological roles, the new leads increase histone 3 lysine 9 acetylation and glucose uptake in cultured cells, while blocking TNF-α production and T lymphocyte proliferation. Notably, the new SIRT6 inhibitors effectively sensitize pancreatic cancer cells to gemcitabine. Finally, studies of compound fingerprinting and pharmacokinetics defined the drug-like properties of one of the new SIRT6 inhibitors, potentially allowing for subsequent in vivo proof-of-concept studies. In conclusion, new SIRT6 inhibitors with a salicylate-like structure were identified, which are active in cells and could potentially find applications in disease conditions, including cancer and immune-mediated disorders.

Original languageEnglish
Pages (from-to)5849-5858
Number of pages10
JournalBioorganic and Medicinal Chemistry
Volume25
Issue number20
DOIs
Publication statusPublished - 2017

Fingerprint

Salicylates
Immunosuppressive Agents
Cells
gemcitabine
Chemoradiotherapy
Acetylation
Neoplasms
Pharmacokinetics
T-cells
Immune System Diseases
Pancreatic Neoplasms
Pharmaceutical Preparations
Computer Simulation
NAD
Histones
Lysine
Cultured Cells
Radiotherapy
T-Lymphocytes
Glucose

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Damonte, P., Sociali, G., Parenti, M. D., Soncini, D., Bauer, I., Boero, S., ... Bruzzone, S. (2017). SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. Bioorganic and Medicinal Chemistry, 25(20), 5849-5858. https://doi.org/10.1016/j.bmc.2017.09.023

SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. / Damonte, Patrizia; Sociali, Giovanna; Parenti, Marco Daniele; Soncini, Debora; Bauer, Inga; Boero, Silvia; Grozio, Alessia; Holtey, Maria von; Piacente, Francesco; Becherini, Pamela; Sanguineti, Roberta; Salis, Annalisa; Damonte, Gianluca; Cea, Michele; Murone, Maximilien; Poggi, Alessandro; Nencioni, Alessio; Del Rio, Alberto; Bruzzone, Santina.

In: Bioorganic and Medicinal Chemistry, Vol. 25, No. 20, 2017, p. 5849-5858.

Research output: Contribution to journalArticle

Damonte, P, Sociali, G, Parenti, MD, Soncini, D, Bauer, I, Boero, S, Grozio, A, Holtey, MV, Piacente, F, Becherini, P, Sanguineti, R, Salis, A, Damonte, G, Cea, M, Murone, M, Poggi, A, Nencioni, A, Del Rio, A & Bruzzone, S 2017, 'SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects', Bioorganic and Medicinal Chemistry, vol. 25, no. 20, pp. 5849-5858. https://doi.org/10.1016/j.bmc.2017.09.023
Damonte, Patrizia ; Sociali, Giovanna ; Parenti, Marco Daniele ; Soncini, Debora ; Bauer, Inga ; Boero, Silvia ; Grozio, Alessia ; Holtey, Maria von ; Piacente, Francesco ; Becherini, Pamela ; Sanguineti, Roberta ; Salis, Annalisa ; Damonte, Gianluca ; Cea, Michele ; Murone, Maximilien ; Poggi, Alessandro ; Nencioni, Alessio ; Del Rio, Alberto ; Bruzzone, Santina. / SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects. In: Bioorganic and Medicinal Chemistry. 2017 ; Vol. 25, No. 20. pp. 5849-5858.
@article{be274ac32a9c4f3384493049c9ae89c8,
title = "SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects",
abstract = "The NAD+-dependent deacetylase SIRT6 is an emerging cancer drug target, whose inhibition sensitizes cancer cells to chemo-radiotherapy and has pro-differentiating effects. Here we report on the identification of novel SIRT6 inhibitors with a salicylate-based structure. The new SIRT6 inhibitors show improved potency and specificity compared to the hit inhibitor identified in an in silico compound screen. As predicted based on SIRT6 biological roles, the new leads increase histone 3 lysine 9 acetylation and glucose uptake in cultured cells, while blocking TNF-α production and T lymphocyte proliferation. Notably, the new SIRT6 inhibitors effectively sensitize pancreatic cancer cells to gemcitabine. Finally, studies of compound fingerprinting and pharmacokinetics defined the drug-like properties of one of the new SIRT6 inhibitors, potentially allowing for subsequent in vivo proof-of-concept studies. In conclusion, new SIRT6 inhibitors with a salicylate-like structure were identified, which are active in cells and could potentially find applications in disease conditions, including cancer and immune-mediated disorders.",
author = "Patrizia Damonte and Giovanna Sociali and Parenti, {Marco Daniele} and Debora Soncini and Inga Bauer and Silvia Boero and Alessia Grozio and Holtey, {Maria von} and Francesco Piacente and Pamela Becherini and Roberta Sanguineti and Annalisa Salis and Gianluca Damonte and Michele Cea and Maximilien Murone and Alessandro Poggi and Alessio Nencioni and {Del Rio}, Alberto and Santina Bruzzone",
year = "2017",
doi = "10.1016/j.bmc.2017.09.023",
language = "English",
volume = "25",
pages = "5849--5858",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "20",

}

TY - JOUR

T1 - SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects

AU - Damonte, Patrizia

AU - Sociali, Giovanna

AU - Parenti, Marco Daniele

AU - Soncini, Debora

AU - Bauer, Inga

AU - Boero, Silvia

AU - Grozio, Alessia

AU - Holtey, Maria von

AU - Piacente, Francesco

AU - Becherini, Pamela

AU - Sanguineti, Roberta

AU - Salis, Annalisa

AU - Damonte, Gianluca

AU - Cea, Michele

AU - Murone, Maximilien

AU - Poggi, Alessandro

AU - Nencioni, Alessio

AU - Del Rio, Alberto

AU - Bruzzone, Santina

PY - 2017

Y1 - 2017

N2 - The NAD+-dependent deacetylase SIRT6 is an emerging cancer drug target, whose inhibition sensitizes cancer cells to chemo-radiotherapy and has pro-differentiating effects. Here we report on the identification of novel SIRT6 inhibitors with a salicylate-based structure. The new SIRT6 inhibitors show improved potency and specificity compared to the hit inhibitor identified in an in silico compound screen. As predicted based on SIRT6 biological roles, the new leads increase histone 3 lysine 9 acetylation and glucose uptake in cultured cells, while blocking TNF-α production and T lymphocyte proliferation. Notably, the new SIRT6 inhibitors effectively sensitize pancreatic cancer cells to gemcitabine. Finally, studies of compound fingerprinting and pharmacokinetics defined the drug-like properties of one of the new SIRT6 inhibitors, potentially allowing for subsequent in vivo proof-of-concept studies. In conclusion, new SIRT6 inhibitors with a salicylate-like structure were identified, which are active in cells and could potentially find applications in disease conditions, including cancer and immune-mediated disorders.

AB - The NAD+-dependent deacetylase SIRT6 is an emerging cancer drug target, whose inhibition sensitizes cancer cells to chemo-radiotherapy and has pro-differentiating effects. Here we report on the identification of novel SIRT6 inhibitors with a salicylate-based structure. The new SIRT6 inhibitors show improved potency and specificity compared to the hit inhibitor identified in an in silico compound screen. As predicted based on SIRT6 biological roles, the new leads increase histone 3 lysine 9 acetylation and glucose uptake in cultured cells, while blocking TNF-α production and T lymphocyte proliferation. Notably, the new SIRT6 inhibitors effectively sensitize pancreatic cancer cells to gemcitabine. Finally, studies of compound fingerprinting and pharmacokinetics defined the drug-like properties of one of the new SIRT6 inhibitors, potentially allowing for subsequent in vivo proof-of-concept studies. In conclusion, new SIRT6 inhibitors with a salicylate-like structure were identified, which are active in cells and could potentially find applications in disease conditions, including cancer and immune-mediated disorders.

UR - http://www.scopus.com/inward/record.url?scp=85029797029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029797029&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2017.09.023

DO - 10.1016/j.bmc.2017.09.023

M3 - Article

VL - 25

SP - 5849

EP - 5858

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 20

ER -